Silexion Therapeutics Corp (SLXN)

Currency in USD
1.5000
+0.0600(+4.17%)
Closed·
1.4500-0.0500(-3.33%)
·
Advertisement
Trading near 52-week Low
SLXN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.26001.6100
52 wk Range
1.2600777.1200
Key Statistics
Prev. Close
1.44
Open
1.46
Day's Range
1.26-1.61
52 wk Range
1.26-777.12
Volume
49.47K
Average Volume (3m)
424.71K
1-Year Change
-99.747%
Book Value / Share
2.52
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
SLXN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
119.9999
Upside
+7,899.99%
Members' Sentiments
Bearish
Bullish
ProTips
RSI suggests the stock is in oversold territory

Silexion Therapeutics Corp News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 119.9999
(+7,899.99% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Maxim Group
Hold---Downgrade29/07/2026
Litchfield Hills Research
Buy6.00+300.00%-New Coverage15/12/2025

Earnings

Latest Release
13/11/2026
EPS / Forecast
-115.56 / -364.80
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

Compare SLXN to Peers and Sector

Metrics to compare
SLXN
Peers
Sector
Relationship
P/E Ratio
0.0x−1.5x−0.2x
PEG Ratio
-−0.010.00
Price/Book
7.6x0.0x2.6x
Price / LTM Sales
-3.9x2.7x
Upside (Analyst Target)
-1,347.9%69.6%
Fair Value Upside
Unlock29.0%11.7%Unlock

Silexion Therapeutics Corp operates as a clinical-stage oncology-focused biotechnology company. It engages in the development of treatments for unsatisfactorily treated solid tumor cancers. The company is advancing its lead product candidate, SIL204, a small interfering RNA (siRNA) through Phase 2/3 clinical evaluation. It focuses on therapeutic advancements in the field of oncology, as well as developing its lead product candidate for pancreatic cancer. The company was founded in 2008 and is headquartered in Ramat Gan, Israel.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
0.000.00%0.00
Other Institutional Investors
11.47K4.95%16.51K
Public Companies & Retail Investors
220.21K95.05%317.10K
Total
231.68K100.00%333.62K

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Warberg Asset Management LLC4.05%9,39414
UBS Asset Management AG0.31%7261

People Also Watch

0.0026
SHFS
-50.24%
1.010
DKI
-11.40%
0.7320
AMOD
-6.50%
1.230
BIYA
-4.65%
0.0350
NIVF
-79.47%

FAQ

What Is the Silexion Therapeutics (NASDAQ: SLXN) Share Price Today?

The Silexion Therapeutics stock price today is 1.5000 USD.

What Stock Exchange Does Silexion Therapeutics (SLXN) Trade On?

Silexion Therapeutics is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for Silexion Therapeutics?

The stock symbol (also called a 'ticker') for Silexion Therapeutics is "SLXN."

What Is the Current Silexion Therapeutics Market Capitalisation?

As of today, Silexion Therapeutics (NASDAQ: SLXN) market cap is 333.6100K USD.

What Is Silexion Therapeutics's (SLXN) Earnings Per Share (TTM)?

The Silexion Therapeutics EPS is currently -929.85 (Trailing Twelve Months).

When Is the Next Silexion Therapeutics Earnings Date?

Silexion Therapeutics's next earnings report will be released on 23/03/2027.

Is SLXN a Buy or Sell From a Technical Analyst Perspective?

Based on today's Silexion Therapeutics moving averages and other technical indicators, the daily buy/sell signal for SLXN stock is Strong Sell.

How Many Times Has Silexion Therapeutics Stock Split?

Silexion Therapeutics has split 4 times. (See the SLXN stock split history page for full effective split date and price information.)

How Many Employees Does Silexion Therapeutics Have?

Silexion Therapeutics has 14 employees, based on their latest Companies House report.

What is the current trading status of Silexion Therapeutics (NASDAQ: SLXN)?

As of 20/11/2026, Silexion Therapeutics (SLXN) is trading at a share price of 1.5000 USD, with a previous close of 1.4400 USD. The stock has fluctuated within a day range of 1.2600 USD to 1.6100 USD, while its 52-week range spans from 1.2600 USD to 777.1200 USD.

What Is Silexion Therapeutics (SLXN) Price Target According to Analysts?

The average 12-month price target for Silexion Therapeutics is 119.9999 USD, with a high estimate of 119.9999 USD and a low estimate of 119.9999 USD. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +7,899.99% Upside potential.

What Is the SLXN Premarket Price?

SLXN's last pre-market stock price is 1.5800 USD. The pre-market share volume is 4,070.0000, and the stock has decreased by 0.1400, or 9.7200%.

What Is the SLXN After Hours Price?

SLXN's last after hours stock price is 1.4500 USD, the stock has decreased by -0.0500, or -3.3300%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.